Skip to main content
Yunnan Botanee Bio-technology Group Co.,Ltd. logo

Yunnan Botanee Bio-technology Group Co.,Ltd. — Investor Relations & Filings

Ticker · 300957 ISIN · CNE100004G74 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2026-05-20 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300957

About Yunnan Botanee Bio-technology Group Co.,Ltd.

https://www.botanee.com.cn

Yunnan Botanee Bio-technology Group Co.,Ltd. focuses on the research, development, and commercialization of dermatological products specifically formulated for sensitive skin. The company’s core strategy involves the integration of clinical dermatology with botanical active ingredients derived from high-altitude plant resources. Its flagship brand, Winona, is recognized for its evidence-based approach to skin barrier repair and inflammatory skin conditions. The product portfolio extends to specialized lines including Winona Baby for pediatric care and AOXMED for premium anti-aging solutions. Botanee maintains a strong emphasis on research and development, collaborating with dermatological experts and medical institutions to ensure product safety and efficacy. The company utilizes advanced biotechnology to extract bioactive compounds, positioning its offerings at the intersection of medical science and professional skincare.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement of the company’s 2025 annual profit distribution (cash dividend) implementation plan, including dividend amount per share, record date, ex-dividend date, tax treatment, and payment method. It contains full details on dividend distribution rather than being a full financial report or meeting materials. This fits the definition of a Notice of Dividend Amount (DIV).
2026-05-20 Chinese
北京市君合律师事务所关于云南贝泰妮生物科技集团股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The provided text is a legal opinion letter (“法律意见书”) by a law firm addressing the legality of the company’s 2025 Annual General Meeting procedures, attendees, and vote results. It is not the Annual Report itself, nor a proxy solicitation statement or vote‐only announcement. It serves as an attestation and compliance opinion rather than substantive financial or governance disclosures. Under the certification rule and fallback guidance for compliance or attestation letters, this should be classified as a Regulatory Filing (RNS).
2026-05-18 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an official announcement detailing the resolutions passed at the 2025 annual general shareholders’ meeting, including precise voting results for each proposal. It is not the meeting materials themselves nor an invitation or proxy statement, but the formal declaration of voting outcomes. Hence, it fits the “Declaration of Voting Results & Voting Rights Announcements” category (Code: DVA).
2026-05-18 Chinese
关于举行2025年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online earnings presentation meeting (业绩说明会) for the fiscal year 2025. It references that the 2025 Annual Report has already been disclosed on April 27, 2026, and invites investors to participate in a live webcast on May 12, 2026. The document does not contain the actual financial results or detailed financial data but rather informs about the upcoming earnings call event. Therefore, it is best classified as an Investor Presentation (IP) announcement, as it focuses on the company's financial performance presentation to investors rather than the report itself or a simple announcement of report publication.
2026-05-08 Chinese
关于回购公司股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the board approval of the buyback plan, the intended amount and price limits, and states that as of the report date no shares have been repurchased yet. It references previous announcements about the buyback plan and complies with regulatory disclosure requirements for buyback progress. The document does not contain financial statements or earnings data, nor is it a full report or presentation. It is a clear update on the company's transaction in its own shares (share repurchase). Therefore, the appropriate classification is Transaction in Own Shares (POS). The document length is short and focused on buyback progress, not a report publication or regulatory filing.
2026-05-07 Chinese
关于2025年度计提资产减值准备及核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by a company regarding the 2025 fiscal year asset impairment provisions and asset write-offs. It includes detailed accounting policies, impairment testing methods, and the impact on financial results. The document references the company's board and audit committee meetings approving the impairment provisions. It is not a full annual or interim report but a specific announcement about asset impairment provisions for the fiscal year 2025. The document length is under 5,000 characters and contains detailed financial data related to impairment provisions, not just a notice of report publication. This type of document fits best under the category of Regulatory Filings (RNS) because it is a regulatory announcement about accounting estimates and provisions, not a full financial report like an Annual Report (10-K) or Interim Report (IR).
2026-04-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.